Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:27:33.809Z.
Calculation as of: 2026-10-06T19:27:33.809Z.
Quote observation: 2026-10-06T19:25:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$2.13B
EV/Sales Ratio
4.92x
TTM Avg
6.40x
3Y Avg
5.45x
5Y Avg
3.85x
Market Cap
$2.12B
EV/Sales Ratio
N/A
TTM Avg
25.05x
3Y Avg
18.35x
5Y Avg
18.35x
Market Cap
$2.19B
EV/Sales Ratio
11.02x
TTM Avg
3.07x
3Y Avg
2.80x
5Y Avg
3.21x
Market Cap
$2.11B
EV/Sales Ratio
1.43x
TTM Avg
1.47x
3Y Avg
1.64x
5Y Avg
1.69x
Market Cap
$2.07B
EV/Sales Ratio
18097.88x
TTM Avg
5446.14x
3Y Avg
1995.96x
5Y Avg
1504.57x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pharvaris N.V. (PHVS) | $2.15B | N/A | N/A | N/A | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | 4.92x | 6.40x | 5.45x | 3.85x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.12B | N/A | 25.05x | 18.35x | 18.35x |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.19B | 11.02x | 3.07x | 2.80x | 3.21x |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 1.43x | 1.47x | 1.64x | 1.69x |
| Vera Therapeutics, Inc. (VERA)vs › | $2.08B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.08B | 6.89x | 5.02x | 9.93x | 18.06x |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.23B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 18097.88x | 5446.14x | 1995.96x | 1504.57x |
| Vericel Corporation (VCEL)vs › | $2.05B | 6.60x | 7.02x | 9.23x | 9.34x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
